Aclaris Therapeutics, Inc. (ACRS) Stock

Aclaris Therapeutics, Inc. (ACRS) is a Healthcare stock trading at $4.47 (as of 2026-06-18), with a market capitalization of $617.31M and a trailing P/E of -7.7. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Unable to draft a compliant description because the required primary source (Aclaris Therapeutics, Inc. SEC 10-K Item 1, Business text) was not provided. Please paste the SEC 10-K “Business” (Item 1) section so I can summarize only facts from that source.

Valuation — source: SEC EDGAR (first-party)
Price	$4.47
Market Cap	$617.31M
P/E Ratio	-7.7
EV / EBITDA	-7.2
Price / Book	4.20
Price / Sales	72.11
DCF Value (model)	$-6.50
DCF Upside vs Price	-245.3%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$7.83M
Net Margin	-829.6%
Return on Equity	-48.5%
Current Ratio	4.03
Revenue Growth (YoY)	-58.2%
EPS Growth (YoY)	-69.0%
FCF Growth (YoY)	133.8%

Financial Health — source: SEC EDGAR
Altman Z-Score	-3.82 (distress)

Valuation vs Sector & Industry
Stock P/E	-7.7
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-136.9%
vs Industry	-145.3%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BML Capital Management, LLC ($53.44M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Neal S. Walker
Employees	61
Country	US
IPO Date	2015-10-06

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.